Browse > Article
http://dx.doi.org/10.4046/trd.2011.70.1.21

Comparative Analysis of Peptide Nucleic Acid (PNA)-Mediated Real-Time PCR Clamping and DNA Direct Sequencing for EGFR Mutation Detection  

Kim, Hee-Joung (Department of Internal Medicine, Konkuk University School of Medicine)
Kim, Wan-Seop (Department of Pathology, Konkuk University School of Medicine)
Shin, Kyeong-Cheol (Department of Internal Medicine, Yeungnam University College of Medicine)
Lee, Gwan-Ho (Department of Internal Medicine, Yeungnam University College of Medicine)
Kim, Mi-Jin (Department of Pathology, Yeungnam University College of Medicine)
Lee, Jeong-Eun (Department of Internal Medicine, Chungnam National University College of Medicine)
Song, Kyu-Sang (Department of Pathology, Chungnam National University College of Medicine)
Kim, Sun-Young (Department of Internal Medicine, Chungnam National University College of Medicine)
Lee, Kye-Young (Department of Internal Medicine, Konkuk University School of Medicine)
Publication Information
Tuberculosis and Respiratory Diseases / v.70, no.1, 2011 , pp. 21-27 More about this Journal
Abstract
Background: Although the gold standard method for research trials on epidermal growth factor receptor (EGFR) mutations has been direct sequencing, this approach has the limitations of low sensitivity and of being time-consuming. Peptide nucleic acid (PNA)-mediated polymerase chain reaction (PCR) clamping is known to be a more sensitive detection tool. The aim of this study was to compare the detection rate of $EGFR$ mutation and EGFR-tyrosine kinase inhibitor (TKI) responsiveness according to $EGFR$ mutation status using both methodologies. Methods: Clinical specimens from 112 NSCLC patients were analyzed for $EGFR$ mutations in exons 18, 19, 20, and 21. All clinical data and tumor specimens were obtained from 3 university hospitals in Korea. After genomic DNA was extracted from paraffin-embedded tissue specimens, both PNA-mediated PCR clamping and direct-sequencing were performed. The results and clinical response to $EGFR$-TKIs were compared. Results: Sequencing revealed a total of 35 (22.9%) mutations: 8 missense mutations in exon 21 and 26 deletion mutations in exon 19. PNA-mediated PCR clamping showed the presence of genomic alterations in 45 (28.3%) samples, including the 32 identified by sequencing plus 13 additional samples (6 in exon 19 and 7 in exon 21). Conclusion: PNA-mediated PCR clamping is simple and rapid, as well as a more sensitive method for screening of genomic alterations in $EGFR$ gene compared to direct sequencing. This data suggests that PNA-mediated PCR clamping should be implemented as a useful screening tool for detection of $EGFR$ mutations in clinical setting.
Keywords
Peptide Nucleic Acids; Molecular Sequencing Data; Receptor, Epidermal Growth Factor; Epidermal Growth Factor;
Citations & Related Records
Times Cited By KSCI : 3  (Citation Analysis)
Times Cited By SCOPUS : 2
연도 인용수 순위
1 Tanaka T, Nagai Y, Miyazawa H, Koyama N, Matsuoka S, Sutani A, et al. Reliability of the peptide nucleic acid-locked nucleic acid polymerase chain reaction clamp-based test for epidermal growth factor receptor mutations integrated into the clinical practice for non-small cell lung cancers. Cancer Sci 2007;98:246-52.   DOI   ScienceOn
2 Nielsen PE, Egholm M. An introduction to peptide nucleic acid. Curr Issues Mol Biol 1999;1:89-104.
3 Lee KY, Kim HJ, Kim SJ, Yoo GH, Kim WD, Oh SY, et al. PNA-mediated PCR clamping for the detection of EGFR mutations in non-small cell lung cancer. Tuberc Respir Dis 2010;69:271-8.   DOI
4 Hwang TS. Molecular biologic techniques in cytopathologic diagnosis. Korean J Pathol 2009;43:387-92.   DOI   ScienceOn
5 Dahabreh IJ, Linardou H, Siannis F, Kosmidis P, Bafaloukos D, Murray S. Somatic EGFR mutation and gene copy gain as predictive biomarkers for response to tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res 2010;16:291-303.   DOI   ScienceOn
6 Neal JW, Sequist LV. Targeted therapies: optimal firstline therapy for NSCLC with EGFR mutations. Nat Rev Clin Oncol 2010;7:71-2.   DOI   ScienceOn
7 Rosell R, Viteri S, Molina MA, Benlloch S, Taron M. Epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment in advanced nonsmallcell lung cancer. Curr Opin Oncol 2010;22:112-20.   DOI   ScienceOn
8 Choi J, Cho M, Oh M, Kim H, Kil MS, Park H. PNA-mediated real-time PCR clamping for detection of EGFR mutations. Bull Korean Chem Soc 2010;31:3525-9.   DOI
9 Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007;7:169-81.   DOI   ScienceOn
10 Sakurada A, Lara-Guerra H, Liu N, Shepherd FA, Tsao MS. Tissue heterogeneity of EGFR mutation in lung adenocarcinoma. J Thorac Oncol 2008;3:527-9.   DOI   ScienceOn
11 Wang J, Ramakrishnan R, Tang Z, Fan W, Kluge A, Dowlati A, et al. Quantifying EGFR alterations in the lung cancer genome with nanofluidic digital PCR arrays. Clin Chem 2010;56:623-32.   DOI   ScienceOn
12 Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-57.   DOI   ScienceOn
13 Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-8.   DOI   ScienceOn
14 Ciardiello F, Tortora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res 2001;7:2958-70.
15 Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39.   DOI   ScienceOn
16 Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-500.   DOI
17 Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004;101:13306-11.   DOI   ScienceOn
18 Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010;11:121-8.   DOI   ScienceOn
19 Eberhard DA, Giaccone G, Johnson BE; Non-Small-Cell Lung Cancer Working Group. Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting. J Clin Oncol 2008;26:983-94.   DOI   ScienceOn
20 Janne PA, Borras AM, Kuang Y, Rogers AM, Joshi VA, Liyanage H, et al. A rapid and sensitive enzymatic method for epidermal growth factor receptor mutation screening. Clin Cancer Res 2006;12:751-8.   DOI   ScienceOn
21 Chin TM, Anuar D, Soo R, Salto-Tellez M, Li WQ, Ahmad B, et al. Detection of epidermal growth factor receptor variations by partially denaturing HPLC. Clin Chem 2007;53:62-70.
22 Hoshi K, Takakura H, Mitani Y, Tatsumi K, Momiyama N, Ichikawa Y, et al. Rapid detection of epidermal growth factor receptor mutations in lung cancer by the SMart-Amplification Process. Clin Cancer Res 2007;13: 4974-83.   DOI   ScienceOn
23 Nagai Y, Miyazawa H, Huqun, Tanaka T, Udagawa K, Kato M, et al. Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp. Cancer Res 2005;65:7276-82.   DOI   ScienceOn